Localized Therapy in Early- and Intermediate-Stage HCC

Opinion
Video

Medical oncologists outline localized therapy options for patients with early- and intermediate-stage hepatocellular carcinoma.

Recent Videos
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Epistemic closure, broad-scale distribution, and insurance companies are the 3 largest obstacles to implementing new peritoneal surface malignancy care guidelines into practice.
“This is something where this is written by the trainees, for the trainees, and, of course, for all the other clinicians who take care of patients,” said Kiran Turaga, MD, MPH.
“Everyone—patients, doctors—we all want the same thing. We want [patients] to live longer,” said Kiran Turaga, MD, MPH, on patients with peritoneal surface malignancies.
The new peritoneal surface malignancy care guidelines had clinicians gather from every disease state to show increased representation.
These new guidelines aim to alleviate some of the problems caused by patients with peritoneal metastases being diagnosed with the disease in late stages.
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content
Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Novel Agent Meets End Points in COMPETE Trial for GEP-NETs

Paige Britt
October 18th 2025
Article

ITM-11 showed superior PFS and ORR compared with everolimus in patients with gastroenteropancreatic neuroendocrine tumors.

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

A numerically greater response rate with regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.

Regorafenib/Nivolumab Exhibits Nonsuperior Survival in Gastric Cancer

Roman Fabbricatore
October 17th 2025
Article

A numerically greater response rate with regorafenib/nivolumab may encourage a search for more non-chemotherapy combinations for gastric cancer.

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

Marwan G. Fakih, MD
February 24th 2025
Podcast

The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

Safety outcomes, including the treatment-related AEs and AEs leading to treatment discontinuation, were consistent with or without lenvatinib in ESCC.

Lenvatinib-Based Regimen Does Not Significantly Improve OS in Advanced ESCC

Caroline Seymour
October 17th 2025
Article

Meta: Safety outcomes, including the treatment-related AEs and AEs leading to treatment discontinuation, were consistent with or without lenvatinib in ESCC.

Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.

Neoadjuvant FOLFIRINOX Shows Comparable Survival vs Chemoradiation in PDAC

Roman Fabbricatore
October 16th 2025
Article

Serious AEs occurred in 49% of patients treated with FOLFIRNOX vs 43% of patients treated with chemoradiation for pancreatic ductal adenocarcinoma.